Hinweis-Modus ist eingeschaltet Ausschalten
Für eine schnelle Bewegung zwischen den Elementen

Unternehmen: Emergent Biosolutions
LEI 549300YW6TUOX8BE5103

Firmenname
Emergent Biosolutions Inc
Name des Landes
Vereinigte Staaten
Eintragungsland
Vereinigte Staaten
Branche
Pharmazeutische Zubereitung und Biotechnologie
Anleihenschuld
450 Mio. USD

Entdecken Sie die umfangreichste Datenbank

800 000

Anleihen weltweit

Über 400

Kursquellen

80 000

Aktien

9 000

ETF

Verwalten Sie Ihr Portfolio auf effizienteste Weise
Bond-Screener
Watchlist
Excel-Add-In
Zugang erhalten

Letzte Daten zum

Kurse

Anfrage wurde gesendet
Zugang verboten
Anfrage senden
Die von Informationsanbietern bereitgestellten Kurse haben indikativen Charakter

Profil

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense Division and BioSciences Division. It derived substantially all of its product revenues from sales of BioThrax to the United States government, specifically and the United States Department of Health and Human Services (HHS), as well as the United States Department of Defense (DoD).

Auszeichnungen

Nachrichten

01/05/2024 Emergent Biosolutions: Costs Associated With Exit Or Disposal Activities, Regulation Fd Disclosure, Financial Statements And Exhibits
29/04/2024 Emergent Biosolutions: Entry Into A Material Definitive Agreement, Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
29/04/2024 Emergent Biosolutions: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Financial Statements And Exhibits
23/04/2024 Emergent Biosolutions: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Financial Statements And Exhibits
13/03/2024 S&P Global Ratings downgrades Local Currency LT credit rating of Emergent Biosolutions to "CCC+"
Alle Nachrichten des Unternehmens

Dokumente

IFRS/US GAAP Finanzberichte

2024
I Q Eng.
2023
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2022
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2021
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2020
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2019
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2018
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2017
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2016
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2015
I Q Eng.
II Q Eng.
III Q Eng.
IV Q Eng.
2014
IV Q Eng.
Alle anzeigen Verstecken
Sie müssen sich einloggen
Sie benötigen einen Zugang

Aktien

Letzte Anleihen

Alle anzeigen

Anleihenschuld nach Währung

Alle anzeigen Verstecken

Codes

  • LEI
    549300YW6TUOX8BE5103
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001367644
  • EIN
    14-1902018

Kredit- und ESG-Ratings

Makroökonomie

Sie müssen sich registrieren , um Zugriff zu erhalten.